Follow-Up of HOVON-65/GMMG-HD4: Bortezomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma


Follow-Up of HOVON-65/GMMG-HD4: Bortezomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Sagar Lonial, MD (1/22/14)
Sonneveld P et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: Extended follow-up of the HOVON-65/GMMG-HD4 trial. Proc ASH 2013;Abstract 404.

Dr Lonial is Professor, Vice Chair of Clinical Affairs and Director of Translational Research for the B-Cell Malignancy Program in the Department of Hematology and Medical Oncology at the Emory University School of Medicine Winship Cancer Institute in Atlanta, Georgia.